Immunic's IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease Study
Immunic Inc (NASDAQ: IMUX) has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis (PSC), a rare liver disease characterized by inflamed and narrow bile ducts, thus preventing bile from flowing correctly.
27.3% of the patients in the per-protocol population had a clinically relevant reduction of serum alkaline phosphatase higher than 25% at week 24, without an increase in liver biochemistry of more than 33%, as compared to baseline.
Regarding the secondary objectives of the study, no changes in aspartate aminotransferase, alanine aminotransferase, or total, direct or indirect bilirubin were observed compared to baseline.
The study also found that IMU-838 is safe and well-tolerated.
Yesterday, the company announced IMU-838 data from 204 COVID-19 patients who showed clinical activity evidence compared to placebo.
IMU-838 is an oral selective immune modulator that inhibits activated immune cells' intracellular metabolism by blocking the enzyme dihydroorotate dehydrogenase (DHODH).
Immunic's management team will host a conference call and webcast today at 8:00 a.m. ET.
Price Action: IMUX shares are up by 3.99% at $21.10 in the premarket session on the last check Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
